LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced unaudited fourth quarter and full year 2011 total CUBICIN® (daptomycin for injection) net product revenues. Not included in this news release are any revenues associated with the recent acquisition of Adolor, which will be addressed in our full earnings news release and conference call on January 19, 2012. The table below does include service revenues associated with Cubist’s co-promotion of Optimer Pharmaceuticals’ DIFICID® and other revenues, which increased primarily due to the achievement of a $5.0 million sales milestone that we received from our international partner, Novartis AG.
